This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2002.
Company Filing History:
1 out of 834,411 Years Active: 2002
Title: Soji Bitoh: Innovator in Allergy Treatment
Introduction
Soji Bitoh is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of allergy treatment through his innovative research and patents. His work focuses on the inactivation of granulocytes, which plays a crucial role in managing allergic responses.
Latest Patents
Soji Bitoh holds a patent for the invention titled "Inactivation of granulocytes in the treatment of established allergic responses." This invention is based on the discovery that an essentially nonallergenic covalent conjugate of a model allergen, ovalbumin (OA), and monomethoxypolyethylene glycol (mPEG) is capable of inactivating in vivo and ex vivo granulocytes sensitized with anti-OA IgE antibodies. As a result of the inactivation of the granulocytes, subsequent challenges with OA do not lead to degranulation and the consequent release of vasoactive compounds from the granules of these cells. These findings provide a basis for treating symptoms of an already established immune response against allergens.
Career Highlights
Throughout his career, Soji Bitoh has focused on advancing medical treatments for allergies. His innovative approach to inactivating granulocytes has the potential to change the way allergic responses are managed. With 1 patent to his name, he continues to contribute to the field of immunology.
Collaborations
Soji Bitoh has collaborated with various professionals in his field, including his coworker Alec Sehon. Their joint efforts have furthered research and development in allergy treatments.
Conclusion
Soji Bitoh's work in the inactivation of granulocytes represents a significant advancement in allergy treatment. His innovative patent provides a promising avenue for managing allergic responses effectively.